seneste årsrapport - Sundhed.dk

Khoo TL, Vangsted AJ, Joshua D, Gibson J. “Interferon-alpha in the Treatment of Multiple Myeloma . "Interferonalpha2
in the Treatment of Haematological Malignancies. Status and Perspectives". Current Drug Targets, 2011,
12: 437-446.
Larsen LH, Lund T, Vilholm OJ, Plesner T. Anti-myelin associated glycoprotein neuropathy responding to
lenalidomide. Leuk Res, 2011; 35:e198-9.
Ludwig H, Beksac M, Bladé J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach J, Einsele H, Facon T,
Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal da Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi
H, Plesner T, San-Miguel J, Sonneveld P, Udvardy M, Sondergeld P, Palumbo A. Multiple myeloma treatment
strategies with novel agents in 2011: a European perspective. Oncologist, 2011; 16: 388-403.
Mellstedt H, Gimsing P, Waage A. Treatment of myeloma when high dose therapy is not possible. New drugs-alternatives
for elderly patients. Lakartidningen. 2011 Oct 19-25;108(42):2090-4. Review.
Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L, Boccadoro M, Cavo M,
Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hàjek R, Johnsen HE, Leal
Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P. Personalized
therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network
(EMN). Blood, 2011; 118: 4519-29.
Paiva B, Pérez-Andrés M, Vídriales MB, Almeida J, de las Heras N, Mateos MV, López-Corral L, Gutiérrez NC,
Blanco J, Oriol A, Hernández MT, de Arriba F, de Coca AG, Terol MJ, de la Rubia J, González Y, Martín A, Sureda
A, Schmidt-Hieber M, Schmitz A, Johnsen HE, Lahuerta JJ, Bladé J, San-Miguel JF, Orfao A; GEM (Grupo
Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas); Myeloma Stem
Cell Network (MSCNET). Competition between clonal plasma cells and normal cells for potentially overlapping
bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
Leukemia, 2011; 25: 697-706.
Retningslinje for diagnostik og behandling af myelomatose. DMSG, 2011. www.myeloma.dk
Retningslinje for MGUS. DMSG, 2011. www.myeloma.dk
Toftmann, CT. Myelomatose - status for analysen frie lette kæder i serum. BestPractice Hæmatologi, 2011; 2: 41-46.
van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau
H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A. Treatment of
relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev, 2011; 37: 266-83.
Vangsted AJ, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Nexø BA, Vogel U. Single
nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients
treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib. Ann
Hematol, 2011; 90:1173-81.
Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gregersen H, Nexø BA, Vogel UB. The
importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose
treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP. Ann Hematol, 2011; 90:
675-84.
Årsrapport 2010 for Dansk Myelomatose Studie Gruppe og den landsdækkende myelomatose database. 2011.
www.myeloma.dk
Dansk Myelomatose Studie Gruppe side 64 Årsrapport 2011